Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: A case report and review of the literature

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 1048-1052

  Dalgleish, Angus ^a   Featherstone, Peter ^b   Vlassov, Viatcheslav ^c   Rogosnitzky, Moshe ^d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c MedInsight Research Institute   (United Kingdom)

^d MedInsight Research Institute   (Israel)

Author keywords

CCR7; CD20; Generalized lymphadenopathy; Prostate cancer; Pseudolymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB;

ADENOCARCINOMA; BLOOD; CASE REPORT; HUMAN; IMMUNOLOGY; LYMPHATIC DISEASES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; HUMANS; KALLIKREINS; LYMPHATIC DISEASES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84892416943     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0063-z     Document Type: Review

References (33)

1. Oster MW, Wolff M, Starrett S (1979) Prostate cancer mimicking malignant lymphoma. Med Pediatr Oncol 7:387-392
2. Stein BS, Shea FJ (1983) Metastatic carcinoma of the prostate presenting radiographically as lymphoma. J Urol 130:362-364
3. Liel Y, Biderman A, Biran C et al (1987) Carcinoma of the prostate clinically and radiologically simulating malignant lymphoma. J Surg Oncol 35:113-116
4. Phillips SM, Ferry DR, Lee SJ (1994) Carcinoma of the prostate mimicking lymphoma. Br J Urol 73:590-591
5. Ahn MJ, Oh SJ, Lee YY et al (1997) A case of prostate cancer in 34 year old man presenting with generalized lymphadenopathy mimicking malignant lymphoma. J Korean Med Sci 12:262-265
6. Oyan B, Engin H, Yalcin S (2002) Generalized lymphadenopathy: a rare presentation of disseminated prostate cancer. Med Oncol Northwood Lond Engl 19:177-179. doi: 10.1385/MO:19:3:177
7. Biyani CS, Basu S, Bottomley DM, Shah TK (2003) Prostatic adenocarcinoma masquerading as lymphoma and presentation with axillary-subclavian vein thrombosis. Urol Oncol 21:3-6
8. Heresi GA, Wang J, Taichman R et al (2005) Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol 23:261-267. doi: 10.1016/j.urolonc.2005.02.004
9. Moura FM, Garcia LT, Castro LPF, Ferrari TCA (2006) Prostate adenocarcinoma manifesting as generalized lymphadenopathy. Urol Oncol 24:216-219. doi: 10.1016/j.urolonc.2005.06.022
10. Saad S, Hayek T, Vlodavsky E, et al. Generalized lymphadenopathy as the first manifestation of prostatic cancer. Gd Rounds 10:67-70.
11. Benderli-Cihan Y, Deniz K, Sofikerim M (2011) A Case of Prostate Adenocarcinoma In A 67-Year-Old Man Manifesting As Generalized Lymphaenopathy Mimicking Lymphoma. Kulak Burun Boʇaz Ihtis Derg KBB J Ear Nose Throat 14:381-385
12. Cetin B, Cetin Z, Buyukberber S et al (2011) Generalized lymphadenopathy: unusual presentation of prostate adenocarcinoma. Case Rep Urol 2011:439732. doi: 10.1155/2011/439732
13. Krpina K, Oguic R, Pavlovic I et al (2011) Prostate cancer manifesting as generalized lymphadenopathy. Rev Rom Urol 10:72-74
14. Andre F, Cabioglu N, Assi H et al (2006) Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO 17:945-951. doi: 10.1093/annonc/mdl053
15. Kakinuma T, Hwang ST (2006) Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79:639-651. doi: 10.1189/jlb.1105633
16. Zlotnik A, Burkhardt AM, Homey B (2011) Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11:597-606. doi: 10.1038/nri3049
17. Gladson CL, Welch DR (2008) New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biol Ther 7:1849-1851
18. Taichman RS, Cooper C, Keller ET et al (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832-1837
19. López-Giral S, Quintana NE, Cabrerizo M et al (2004) Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 76:462-471. doi: 10.1189/jlb.1203652
20. Alfonso-Pérez M, López-Giral S, Quintana NE et al (2006) Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol 79:1157-1165. doi: 10.1189/jlb.1105623
21. O'Hayre M, Salanga CL, Kipps TJ et al (2010) Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PloS One 5:e11716. doi: 10.1371/journal.pone.0011716
22. Yang J, Wang S, Zhao G, Sun B (2011) Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res CR 30:51. doi: 10.1186/1756-9966-30-51
23. Buonamici S, Trimarchi T, Ruocco MG et al (2009) CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459:1000-1004. doi: 10.1038/nature08020
24. Ammirante M, Luo J-L, Grivennikov S et al (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464:302-305. doi: 10.1038/nature08782
25. Oosterheert JJ, Budel LM, Vos P, Wittebol S (2007) High levels of serum prostate-specific antigen due to PSA producing follicular non-Hodgkin's lymphoma. Eur J Haematol 79:155-158. doi: 10.1111/j.1600-0609.2007.00883.x
26. Djavan B, Keffer JH, Molberg K, Roehrborn CG (1995) False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney. Urology 45:875-878. doi: 10.1016/S0090-4295(99)80099-5
27. Nadler RB, Humphrey PA, Smith DS et al (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154:407-413
28. Wiernik PH (2008) Serum CA125 and PSA concentrations in patients with lymphoma. Clin Adv Hematol Oncol HO 6:527-531
29. Terris MK, Hausdorff J, Freiha FS (1997) Hematolymphoid malignancies diagnosed at the time of radical prostatectomy. J Urol 158:1457-1459
30. Sella A, Konichezky M, Flex D et al (2000) Low PSA metastatic androgen-independent prostate cancer. Eur Urol 38:250-254
31. Tu S-M, Reyes AO, Fanning T et al (2002) Advanced prostate carcinoma and elevated serum CA-125 level 31. J Clin Oncol Off J Am Soc Clin Oncol 21:2445
32. Cancer Genetics. http://www.cancerindex.org/geneweb/clinkc17.htm (Accessed, September, 2013).
33. Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol Off J Am Soc Clin Oncol 22:735-742. doi: 10.1200/JCO.2004.05.055